Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Impact of CADx on Endoscopists' Histologic Characterization of Diminutive Colorectal Polyps

NCT: NCT07389759 · ACTIVE_NOT_RECRUITING

NCT IDNCT07389759
StatusACTIVE_NOT_RECRUITING
Start Date2026-01-03
Completion2026-04-30

Brief Summary

This study evaluates the impact of CADx assistance on endoscopists' histologic characterization of diminutive colorectal polyps (≤5 mm) during colonoscopy. The primary objective is to determine whether CADx assistance increases the proportion of endoscopists who meet PIVI-related performance thresholds, thereby supporting implementation of the "resect and discard" and "diagnose and leave" strategies in routine clinical practice.

Frequently Asked Questions

What is Impact of CADx on Endoscopists' Histologic Characterization of Diminutive Colorectal Polyps?

Impact of CADx on Endoscopists' Histologic Characterization of Diminutive Colorectal Polyps is a clinical trial registered under NCT07389759. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT07389759?

The current status of NCT07389759 (Impact of CADx on Endoscopists' Histologic Characterization of Diminutive Colorectal Polyps) is: ACTIVE_NOT_RECRUITING.

When did Impact of CADx on Endoscopists' Histologic Characterization of Diminutive Colorectal Polyps start?

Impact of CADx on Endoscopists' Histologic Characterization of Diminutive Colorectal Polyps started on 2026-01-03.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑